InSphero’s leadership team combines many years’ scientific and commercial experience in 3D microtissue engineering, cell based assays, laboratory automation, and industry-scale production and quality assurance. It is complemented by the strategic management expertise of our Board of Directors and Strategic Advisory Board members.
An engineer and laboratory automation expert with 20 years of experience in high-tech startups from chemical processing to medical devices, Jan earned his PhD in Microtechnology and Microfluidics at the University of Neuchêtel.
After 30 years of cumulative experience in Pharma R & D at Janssen Pharmaceuticals Inc (a Johnson & Johnson company) and Novartis, Prof. Wolf joined InSphero as Chief Scientific Officer and has a dual appointment as Professor of Toxicology at the Technical University of Kaiserslautern, Germany. Previously, he was was Senior Director and Global Head of the Mechanistic & Investigative Toxicology (MIT) group at Janssen in Beerse (Belgium), Spring House (PA) and La Jolla (CA). At Novartis, Prof. Wolf led drug development teams as Director of Global Biomarker Group and as Head of Biochemical Cellular Toxicology in Discovery and Investigative Toxicology in Basel. Prof. Wolf earned his PhD at the DKFZ German Cancer Research Center, and
Life-science professional with more than 15 years industry experience, where he held various positions in sales & marketing, product management and business development. His experience ranges from bioinformatics, in vitro diagnostics, and cell-culture in mid-sized and as well as large corporations. Frank holds a PhD in Molecular Microbiology from ETH Zurich.
One of the co-founders of InSphero, Wofgang is expert in production and assay methods for microtissues using laboratory-scale approaches, valuable background in clinical applications of microtissues including islet biology and diabetes drug discovery. Wolfgang earned a PhD in Biochemistry from the University of Zurich.
A seasoned Quality Assurance and Regulatory Affairs professional with 20+ years of experience in pre-market and post-market product development of life science & biotech products and medical devices, including medical device vigilance and post-market surveillance. Hands-on experience in establishing Quality Systems supporting pre-clinical and clinical product development and product release to market. Marion earned her PhD in Molecular Biology at the University of Zurich and an MBA from Webster University, Geneva.
HR professional with more than 10+ years of experience in talent management, learning & development, operational HR, assessment, management development, coaching and training. Katrin earned her PhD in Applied Psychology from the University of Zurich.
Experienced scientist and member of the InSphero team since 2012. David has extensive industry expertise in advanced in vitro model development, standardization, and automation. He holds a PhD in molecular biotechnology from ETH Zurich.
A financial planning and analysis professional with more than 10 years experience in life science and retail companies, Martin has held global finance and auditing positions at several companies, including Bayer and Lonza. He earned his masters degree in international business, controlling, and finance from ESCP Europe, and holds two advanced degrees in biology and industrial engineering, from Justus-Liebig Universität Giessen and the University of Louisville, respectively.
Olivier Frey is Head of Technologies & Platforms and Project Manager of Microphysiological Systems at InSphero AG, and is the former group leader of the Bio Engineering Laboratory of ETHZ (Swiss Federal Institute of Technology in Zürich). He holds a Dr.Sc in Microtechnology from the École Polytechnique Fédérale de Lausanne and an MSc in Microtechnology, Mechanics from ETH Zürich.
Burcak Yesildag is the Head of Islet Solutions Group at InSphero AG. With over 10 years of experience in pancreatic islet biology and diabetes research, she focuses on generating advanced and high-throughput compatible assays and disease models for diabetes drug discovery. Burcak holds a Dr. Sc. degree in Translation Biomedicine from ETHZ (Swiss Federal Institute of Technology Zurich).
A biomedical scientist with extensive experience in cell biology and development of advanced cell models for drug discovery and development, Eva has held research management positions in the pharmaceutical and biotech industries. She earned her PhD in Biology from the University of Wuerzburg in Germany.
Dr. Jürg Gysi, President of the Board, Switzerland
Former CEO, Promega AG Switzerland. Molecular Biologist with more than 30 years of experience in sales, marketing and management in the biotech industry in Switzerland, Germany and the US.
Dr. Jan Lichtenberg, Chief Executive Officer InSphero AG, Member of the InSphero Management Team
Co-founder of InSphero, former Head of R&D and Product Management in medical-device company Hocoma AG and Uwatec AG. Entrepreneur of the Year Switzerland in 2013 and ETH Zurich, University of Neuchâtel, EPF Lausanne and University of Bremen alumni. Founder and former CEO of Advanced Micromachining Tools GmbH.
Thomas Pfisterer, Wild Group Management AG
Heads the Direct Investments activities of the WILD Family Office since beginning of 2015. He joined the Family Office following the sale of WILD Flavors GmbH, one of the world’s leading suppliers of natural ingredients to the food and beverage industry, which he served as Head of Strategic Development directing the company’s global M&A activities since October 2011. Previously, Mr. Pfisterer worked in the investment banking division of Morgan Stanley Bank AG in Frankfurt focusing on M&A and capital market transactions for German healthcare clients. Mr. Pfisterer holds a Master in Finance (MPhil) from Cambridge University, as well as a Bachelor in Economics (B.A. HSG) and a Bachelor in Business Administration (B.A. HSG) both from University of St. Gallen.
Beat Schillig, Founder and President IFJ Institute for Young Entrepreneurs
Serial Entrepreneur and Business Angel.
Dr. Thomas Rinderknecht, Senior Partner at Badertscher Rechtsanwälte
Has served on the board of directors of several biotech, pharma and medtech companies, including Basilea, Speedel AG, Basel, Glycart Biotechnology AG and Ganymed Pharmaceuticals AG. Ph.D. in law from the University of Zurich, admitted to the Bar in Zurich.
Anna Evodokimova, VC Investment Director at Millhouse LLC
Served as the Deputy Head of Corporate Finance from 2006 to May 2015 at Millhouse LLC before. She is also Board member at Cleveland Biolabs, JSC Registrator “R.O.S.T.” “Russia Forest Product”, and “MKM-Logistics”. From 2002 to 2004, Ms. Evdokimova was the Head of Corporate Finance of the major Russian oil and gas company Slavneft. She holds a Bachelor’s degree from Moscow State Linguistic University and Master’s of Business Administration in Finance from Fordham University.
Daniel Kallay, Global Head of New Business Development, Red Bull GmbH
Served as managing director for Red Bull France, Southern Europe and Switzerland previously and is board member on a number of Swiss technology companies. He holds a Master of Economics degree from the University of St. Gallen (HSG) and an advanced leadership degree from Cambridge University.
Patrick Guye, PhD
Extensive experience in life sciences, engineering, business innovation & development, operations and new ventures consulting. Held leadership positions in industry (Sanofi) and academia (Massachusetts Institute of Technology, Princeton University) with focus on cell therapy, 3D cellular models/organoids, synthetic biology, human stem cells, biologics and small molecules development, and precision genomic engineering. Patrick earned his PhD in Molecular Infection Biology from the University of Basel.
Charles Qualls, DVM, PhD, DACVP
A toxicology expert who retired as Executive Director of Investigative Toxicology and Pathology at Amgen Inc. Before working at Amgen, Dr. Qualls served as Director of Molecular and Ultrastructural Pathology at GlaxoSmithKline. Dr. Qualls had a distinguished career over two decades in academia prior to moving into the pharmaceutical industry.
Dr. Med. Sci. Frédéric Lévy
Head of Research & Evaluation at Debiopharm International SA and Associate Professor at the Faculty of Biology and Medicine, University of Lausanne with more than 50 peer-reviewed scientific publications. Dr Med Sc, Biochemistry/Immunology and Postdoc at California Institute of Technology.